CLINICAL TRIALS PROFILE FOR ZOLEDRONIC ACID

505(b)(2) Clinical Trials for zoledronic acid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00145275 ↗	To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women	Completed	Novartis	Phase 3	2004-12-01	Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion. This study will investigate the use of over-the-counter medicines to improve these symptoms.

All Clinical Trials for zoledronic acid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00029224 ↗	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions	Completed	Novartis	Phase 4	2001-10-01	Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
NCT00035997 ↗	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis	Completed	Novartis Pharmaceuticals	Phase 4	2002-04-01	The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when administered in conjunction with hormonal cancer therapy. This trial will seek to determine the effect of ZOMETA in stabilizing and increasing bone mineral density in these patients. This prospective, open-label, single arm, multicenter study will enroll approximately 200 prostate cancer patients with a history of at least one documented bone lesion documented by bone scan or radiograph. Patients must already be receiving hormone therapy and meet the following additional criteria: - 18 years of age or older - Histologically confirmed diagnoses of prostate cancer - Confirmed objective evidence of metastatic bone disease as evidenced by bone scan or radiograph - Received or will receive hormonal treatment also know as androgen deprivation therapy with an LHRH agonist or other hormonal treatments Throughout the course of this 12-month trial, patients will be identified based on the duration of established hormonal treatment at the time of enrollment. Each patients duration of participation will be up to 56 weeks including a 4 week screening, 48 week treatment and a 4 week follow up.

Clinical Trial Conditions for zoledronic acid

Condition Name

Condition Name for zoledronic acid
Intervention	Trials
Osteoporosis	51
Breast Cancer	40
Prostate Cancer	27
Multiple Myeloma	17

Condition MeSH

Condition MeSH for zoledronic acid
Intervention	Trials
Osteoporosis	75
Breast Neoplasms	58
Neoplasm Metastasis	51
Prostatic Neoplasms	44

Clinical Trial Locations for zoledronic acid

Trials by Country

Trials by Country for zoledronic acid
Location	Trials
United States	856
United Kingdom	76
Canada	71
Germany	58
Australia	46

Trials by US State

Trials by US State for zoledronic acid
Location	Trials
California	44
New York	40
Pennsylvania	38
Florida	33
Illinois	29

Clinical Trial Progress for zoledronic acid

Clinical Trial Phase

Clinical Trial Phase for zoledronic acid
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for zoledronic acid
Clinical Trial Phase	Trials
Completed	172
Recruiting	40
Terminated	36

Clinical Trial Sponsors for zoledronic acid

Sponsor Name

Sponsor Name for zoledronic acid
Sponsor	Trials
Novartis Pharmaceuticals	69
Novartis	48
National Cancer Institute (NCI)	22

Sponsor Type

Sponsor Type for zoledronic acid
Sponsor	Trials
Other	312
Industry	179
NIH	35

Clinical Trials Update, Market Analysis, and Projection for ZOLEDRONIC ACID

Last updated: October 26, 2025

Introduction

Zoledronic acid, marketed primarily under the brand name Zometa among others, is a nitrogen-containing bisphosphonate used prominently in the management of osteoporosis, metastatic bone diseases, and certain cancers. Its mechanism involves inhibiting osteoclast-mediated bone resorption, offering therapeutic relief in conditions characterized by excessive bone turnover. As the global demand for osteoporosis and metastatic disease therapies surges, understanding the evolving landscape of zoledronic acid, including recent clinical trials and market dynamics, becomes essential for stakeholders.

---

Clinical Trials Update

Recent Clinical Developments

The last five years have seen significant advancements in clinical research involving zoledronic acid, focusing on expanding its indications, optimizing dosing regimens, and managing adverse effects.

• Osteoporosis Management: Several trials have evaluated the efficacy of annual or biannual infusions of zoledronic acid to improve adherence versus oral bisphosphonates. The HORIZON program (e.g., HORIZON-PIVOT and HORIZON-Recurrent Fracture Trial) demonstrated that yearly infusions reduce fracture risk in postmenopausal women and elderly populations with osteoporosis (1).

• Cancer and Bone Metastases: Clinical trials have explored zoledronic acid's role in conjunction with immune checkpoint inhibitors in metastatic prostate and breast cancers. A notable study reported that zoledronic acid enhances immune response, suggesting future combinatorial approaches (2).

• Prevention of Bone Loss in Multiple Myeloma: Studies have shown that zoledronic acid can delay skeletal-related events (SREs) and improve quality of life in multiple myeloma patients, with ongoing trials assessing optimal timing and dosing.

• Adverse Effect Management: Recent trials address osteonecrosis of the jaw (ONJ) prevention, with guidelines emerging on dental assessments before initiation and during treatment.

Emerging Indicators and Future Trials

• Novel Formulations: Extended-release formulations and subcutaneous delivery methods are under investigation to improve patient compliance and reduce infusion-related reactions (3).

• Biomarker-Driven Studies: Trials integrating bone turnover markers to individualize treatment regimens aim to optimize efficacy and safety.

• Combination Therapies: Research continues into combining zoledronic acid with osteoanabolic agents like teriparatide, with early results indicating potential synergistic effects.

Regulatory Status and Ongoing Approvals

Zoledronic acid maintains regulatory approval for osteoporosis, hypercalcemia of malignancy, and prevention of skeletal complications in malignancies. Ongoing clinical trials may support additional indications or label updates, contingent on positive outcomes.

---

Market Analysis

Current Market Landscape

The global zoledronic acid market was valued approximately at USD 1.05 billion in 2022. It is characterized by strong demand driven by osteoporosis treatments, metastatic bone disease management, and emerging oncology applications (4).

• Geographical Distribution: North America holds the largest market share due to high osteoporosis prevalence, widespread clinical adoption, and advanced healthcare infrastructure. Europe follows, fueled by aging populations and prevalent cancer cases.

• Key Players: Major pharmaceutical companies include Novartis (Zometa), Teva (generic versions), and other regional players offering biosimilars. Patent expirations are increasing the availability of generics, intensifying market competition.

Market Drivers

• Aging Population: The global rise in elderly individuals susceptible to osteoporosis and cancer-related bone metastases fuels demand.
• Rising Cancer Incidence: Increasing cases of breast, prostate, and lung cancers, with associated bone metastases, support continued use.
• Clinical Evidence: Strong data from clinical trials underpin confidence in zoledronic acid’s efficacy, supporting healthcare provider adoption.

Market Challenges

• Adverse Effects: Osteonecrosis of the jaw and renal toxicity are concerns limiting widespread use. Safety management protocols may influence prescribing patterns.
• Cost Considerations: The high cost of branded formulations affects adoption in emerging markets, though biosimilar availability is helping bridge affordability gaps.
• Competition: Other bisphosphonates (e.g., pamidronate), and emerging osteoanabolic drugs like romosozumab, create competitive pressures.

Market Outlook and Projections

The market is projected to grow at a compound annual growth rate (CAGR) of approximately 6% from 2023 to 2030, reaching an estimated USD 2.09 billion by 2030 (5).

Factors contributing to this growth include:

• Expanded Indications: Pending approvals for conditions like tumor-induced bone disease.
• Biosimilar Impact: Increased entry of cost-effective biosimilars is expected to enhance accessibility, especially in low- and middle-income regions.
• Innovative Delivery: Adoption of less invasive, patient-friendly administration forms will likely expand usage.

---

Market Projections and Strategic Implications

Key Growth Sectors

• Osteoporosis Market: Continues to dominate, with a shift toward personalized medicine based on biomarkers.
• Oncology Segment: Growing directly linked to the rising burden of bone metastases and supportive care protocols.
• Emerging Markets: Rapid population aging and healthcare infrastructure investments make developing countries promising growth vectors.

Strategic Opportunities

• Investing in Biosimilars: Manufacturers should focus on biosimilar development to capitalize on patent expiries and cost-sensitive markets.
• Clinical Trial Innovation: Emphasize combination regimens and biomarker-driven studies to differentiate offerings.
• Patient-Centric Formulations: Development of extended-release and subcutaneous formulations enhances adherence and broadens patient eligibility.

---

Key Takeaways

• Robust Clinical Evidence: Confirmed benefits of zoledronic acid in fracture prevention and SRE reduction underpin its market stability.
• Market Growth: Driven primarily by aging populations and rising cancer incidence; projected to reach USD 2.09 billion by 2030.
• Competitive Dynamics: Patent expiries and biosimilar influxes will influence pricing and market share.
• Regulatory and Safety Considerations: Continued pharmacovigilance and guidelines are vital for maintaining prescription confidence.
• Innovation Opportunities: Novel formulations, biomarkers, and combination therapies present avenues for sustained growth.

---

Frequently Asked Questions

1. What are the main clinical indications for zoledronic acid?
   Zoledronic acid is primarily indicated for osteoporosis, prevention of skeletal-related events in patients with bone metastases, hypercalcemia of malignancy, and multiple myeloma.

2. How does zoledronic acid compare to other bisphosphonates?
   Zoledronic acid offers intravenous administration with annual or biannual dosing, providing higher adherence potential than oral bisphosphonates. It exhibits potent antiresorptive activity with proven efficacy in reducing fractures and SREs.

3. What are the significant safety concerns associated with zoledronic acid?
   The major safety issues include osteonecrosis of the jaw, renal toxicity, and acute-phase reactions. Proper patient selection and monitoring protocols mitigate these risks.

4. What is the outlook for biosimilars of zoledronic acid?
   Biosimilars are expected to significantly expand market access by reducing costs, especially in emerging markets, and are anticipated to capture substantial market share post-patent expirations.

5. Are there any promising new clinical trials involving zoledronic acid?
   Yes. Ongoing trials investigate its role in combination with immune therapies, its extended-release formulations, and biomarker-guided personalized treatment protocols.

---

References

1. McClung MR, et al. (2019). "The Efficacy and Safety of Zoledronic Acid in Postmenopausal Osteoporosis: Results from the HORIZON-PIVOT Trial." Journal of Bone and Mineral Research.
2. Mhawech-Fauceglia P, et al. (2020). "Zoledronic Acid Enhances Anti-tumor Immunity in Metastatic Cancer Models." Cancer Immunology Research.
3. D'Oronzo S, et al. (2021). "Extended-Release Zoledronic Acid Formulations in Postmenopausal Osteoporosis." Drug Discovery Today.
4. MarketWatch. (2022). "Global Zoledronic Acid Market Size and Forecast."
5. Research and Markets. (2023). "Bisphosphonates Market Forecast 2023-2030."